Wednesday, October 05, 2016 7:13:27 PM
Today's volume was the second highest daily UP volume since the company's IPO/spin off from Biotime (BTX) in late 2015. On 4/4/16 OCX traded 218K on this headline (ONCOCYTE AND THE WISTAR INSTITUTE ANNOUNCE POSITIVE RESULTS IN THE DEVELOPMENT OF A BLOOD-BASED LUNG CANCER TEST)
We now know the science works and they are simply validating excellent standard of care worthy results (for lung cancer liquid biopsy test) due JAN 17. In DEC 16 we get early data for breast - same platform. They are already working a larger breast trial (hint -- good enough early data for them to continue for breast as the total platform looks strong).
Follow the money? The volume says buy, but no one seems to be here yet. Will they ever come?
The float is thin. BTX will likely sell some of their 14M shares and insiders have loaded up in late August on shares and reasonably priced options at $3.25. This should help the stock consolidate briefly after each leg up as we near late/early year data.
This is certainly a speculative play but results being validated were undeniably strong. So I've been wondering how the stock would trade in the silence as we near more data. I am presuming insiders are very confident as they could not dump shares easily if they suddenly had to, given the small float.
So given all that a 13% high volume pop today with no apparent news seems like a strong indicator -- and a buy signal, at least short term.
Tim
Recent OCX News
- PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology • GlobeNewswire Inc. • 08/20/2024 01:00:00 PM
- Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study • GlobeNewswire Inc. • 08/12/2024 08:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 10:37:23 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 10:25:21 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/09/2024 04:15:11 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:27:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:10:22 PM
- Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Oncocyte Announces August Investor Conferences Participation • GlobeNewswire Inc. • 08/05/2024 08:05:00 PM
- Oncocyte to Announce Second Quarter 2024 Financial Results on August 8 • GlobeNewswire Inc. • 08/01/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 08:05:21 PM
- MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in "Take Advantage of the Moment" Episode • GlobeNewswire Inc. • 07/11/2024 12:00:00 PM
- Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move • GlobeNewswire Inc. • 06/24/2024 04:41:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:10:27 PM
- Oncocyte Appoints Andrea James as Chief Financial Officer • GlobeNewswire Inc. • 06/17/2024 08:05:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/04/2024 09:02:47 PM
- Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study • GlobeNewswire Inc. • 06/03/2024 06:13:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:05:31 PM
- Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine • GlobeNewswire Inc. • 05/30/2024 08:47:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:05:24 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/23/2024 03:26:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 09:18:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:56:24 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/17/2024 09:11:17 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM